Social Media Ideas for Auph

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline...

The Pricing Power Prescription: Unlocking Universal Health Services' Hidden Fair Value

Ascend Wellness Holdings, Inc. (AAWH) Shareholder/Analyst Call Prepared Remarks Transcript

ANC

ANC Anonymous (not verified) Tue, 08/04/2026 - 21:28 field_thread_url https://cafepharma.com/boards/threads/anc.712901/ board name...

Upstart: Undervalued Relative To Its Growth Story

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

Emerging Growth Research Releases Flash Report on First Phosphate; Reiterates Buy Rating and C$4.94 Price Target Followi...

Atlantic Union Bankshares: A Quality Hold

5 Reasons To Buy Clinuvel Pharmaceuticals After Its Nasdaq Uplisting

Up 1,511% in a year, guess which ASX uranium share is storming higher again on Wednesday

Investors are piling into this surging ASX uranium stock again today. But why? The post Up 1,511% in a year, guess which ASX uranium share is storming higher again on Wednesday app...

Aurora Innovation: At The Cusp Of Commercialization, But Execution Remains Key (Rating Upgrade)

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%. The post Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade appeared first on The Motley Fool...

Playing The Biotech Breakout With Insiders

Axsome therapeutics CEO Herriot Tabuteau sells $10.5m in shares

Atlantic Union Bankshares Corporation (AUB) Q2 2026 Earnings Call Transcript

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-...

- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada.

Upstart: Massive Short Squeeze Potential

Abeona (ABEO) Q2 2026 Earnings Call Transcript

ZEVASKYN revenue surged 31% to $11.4 million as treatment network expanded.

AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond

AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for chronic hepatitis B through phase 3 testing and hopefully on to commerci...

Urogen Pharma stock hits 52-week high at 41.45 USD

Transurban Group Stapled Securities (TRAUF) Q4 2026 Earnings Call Transcript

Ardagh Metal Packaging: EBITDA Outperformance Supports Further Upside